Acute myeloid leukemia cells MOLM-13 and SKM-1 established for resistance by azacytidine are crossresistant to P-glycoprotein substrates
- 1 October 2015
- journal article
- Published by Elsevier in Toxicology in Vitro
- Vol. 29 (7) , 1405-1415
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignanciesLeukemia, 2014
- New Insight into P-Glycoprotein as a Drug TargetAnti-Cancer Agents in Medicinal Chemistry, 2013
- RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemiaBlood, 2012
- 5-Azacytidine in myelodysplastic syndromes: A clinical practice guidelineCancer Treatment Reviews, 2011
- NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemiaExpert Opinion on Therapeutic Targets, 2010
- Chemotherapeutic Drug-Induced ABCG2 Promoter Demethylation as a Novel Mechanism of Acquired Multidrug ResistanceNeoplasia, 2009
- Generation and Activation of Multiple Dimeric Transcription Factors within the NF-κB Signaling SystemMolecular and Cellular Biology, 2008
- L1210 cells cultivated under the selection pressure of doxorubicin or vincristine express common mechanisms of multidrug resistance based on the overexpression of P-glycoproteinToxicology in Vitro, 2006
- NF- B constitutes a potential therapeutic target in high-risk myelodysplastic syndromeBlood, 2005
- P-Glycoprotein - Implications of Metabolism of Neoplastic Cells and Cancer TherapyCurrent Cancer Drug Targets, 2005